Lipopolysaccharide Activates Calcineurin in Ventricular Myocytes
Jun Suzuki, MD, PhD*, ,*,
Evelyn Bayna, PhD*,
Hai Ling Li, PhD*,
Erminia Dalle Molle, BS*, and
Wilbur Y.W. Lew, MD, FACC*,
* Cardiology Section, Department of Medicine, V.A. San Diego Healthcare System, San Diego, California
University of California, San Diego, San Diego, California
Manuscript received November 1, 2005;
revised manuscript received August 31, 2006,
accepted September 1, 2006.
* Reprint requests and correspondence: Dr. Wilbur Y. W. Lew, Cardiology Section 111A, V. A. San Diego Healthcare System, 3350 La Jolla Village Drive, San Diego, California 92161. (Email: wlew{at}ucsd.edu).
OBJECTIVES: We investigated whether lipopolysaccharide (LPS), a proximate cause of inflammation, activates calcineurin in cardiac myocytes and if calcineurin regulates apoptosis in this setting.
BACKGROUND: Calcineurin regulates myocardial growth and hypertrophy, but its role in inflammation is unknown. Calcineurin has proapoptotic or antiapoptotic effects depending on the stimuli.
METHODS: Calcineurin activity was measured in left ventricular myocytes from adult Sprague Dawley rats. Cardiac apoptosis was measured by terminal deoxy-nucleotidyl transferase-mediated dUTP nick end-labeling staining and caspase-3 activity after in vitro and in vivo exposure to LPS.
RESULTS: Lipopolysaccharide increased calcineurin activity in myocytes over 1 to 24 h (t 1/2 = 4.8 h) with an EC50 of 0.80 ng/ml LPS (p < 0.05, n = 4). The LPS (10 ng/ml) effects were mimicked by angiotensin II (Ang II) (100 nmol/l); both increased calcineurin activity and induced apoptosis without additive effects (p < 0.05, n = 5 to 9). Lipopolysaccharide and/or Ang II effects were prevented by 1 h pre-treatment with an Ang II type 1 receptor blocker (losartan, 1 µmol/l), calcineurin inhibitor (cyclosporin A, 0.5 µmol/l), calcium chelator (1,2-Bis(2-amino-5-fluorophenoxy)ethane-N,N,N',N'-tetraacetic acid tetrakis(acetoxymethyl) ester, 0.1 µmol/l), or by inhibiting sarcoplasmic reticulum (SR) calcium (Ca)-ATPase (thapsigargin, 1 µmol/l) or SR calcium release channel (ryanodine, 1 µmol/l). Left ventricular apoptosis increased from 4 to 24 h after LPS (1 mg/kg intravenously) in vivo, but not in rats pre-treated with cyclosporin A (20 mg/kg/day subcutaneously) for 3 days (p < 0.05, n = 5).
CONCLUSIONS: In cardiac myocytes, LPS activates calcineurin in association with apoptosis by Ang II and SR calcium-dependent mechanisms. This expands the paradigm for cardiac calcineurin to be activated by low levels of LPS in inflammation and chronic conditions (e.g., infections, smoking, and heart failure).
|
Abbreviations and Acronyms
| | Ang II = angiotensin II | | AT1
= angiotensin II type 1 receptor | | BAPTA-AM = 1,2-Bis(2-amino-5-fluorophenoxy)ethane- N,N,N',N'-tetraacetic acid tetrakis(acetoxymethyl) ester | | LPS = lipopolysaccharide | | MPT = mitochondrial permeability transition pore | | RyR = ryanodine receptor | | SR = sarcoplasmic reticulum | | TLR-4 = Toll-like receptor-4 | | TUNEL = terminal deoxy-nucleotidyl transferase-mediated dUTP nick end-labeling |
|
Related Article
-
Sepsis, Calcineurin, and Cardiac Dysfunction: The Saga of Life and Death
- Sabine Telemaque and Jawahar L. Mehta
J. Am. Coll. Cardiol. 2007 49: 500-501.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
S. Telemaque and J. L. Mehta
Sepsis, Calcineurin, and Cardiac Dysfunction: The Saga of Life and Death
J. Am. Coll. Cardiol.,
January 30, 2007;
49(4):
500 - 501.
[Full Text]
[PDF]
|
 |
|
|